BRAF and neoplasm: On the basis of OncoPanel testing of her tumor from her recurrence surgery, which revealed a BRAF c.1799T>A (p.V600E) mutation (Appendix), she started vemurafenib at 480 mg twice daily, which was dose reduced to 240 mg twice daily because of cutaneous toxicity.